Table 3.
Overall long-term rates of endpoint events and hazard ratios comparing randomized aspirin and placebo groups.
| Endpoint | Aspirin (N = 9,525) | Placebo (N = 9,589) | HR (95% CI) | P value | ||
|---|---|---|---|---|---|---|
| No. (%) of pts with event | Rate per 1000 py | No. (%) of pts with event | Rate per 1000 py | |||
|
| ||||||
| Primary endpoint * | 2110 (22ˑ2) | 28ˑ20 | 2107 (22ˑ0) | 27ˑ89 | 1ˑ01 (0ˑ95, 1ˑ08) | 0ˑ65 |
| Death | 1011 (10ˑ6) | 14ˑ73 | 975 (10ˑ2) | 14ˑ07 | -- | -- |
| Dementia | 569 (6ˑ0) | 8ˑ72 | 571 (6ˑ0) | 8ˑ63 | -- | -- |
| Disability | 530 (5ˑ6) | 8ˑ11 | 561 (5ˑ9) | 8ˑ46 | -- | -- |
|
| ||||||
| Secondary endpoints † | ||||||
| Death | 1547 (16ˑ2) | 19ˑ31 | 1481 (15ˑ4) | 18ˑ25 | 1ˑ06 (0ˑ99, 1ˑ14) | 0ˑ10 |
| Dementia | 601 (6ˑ3) | 8ˑ06 | 616 (6ˑ4) | 8ˑ16 | 0ˑ99 (0ˑ89, 1ˑ11) | 0ˑ87 |
| Disability | 622 (6ˑ5) | 8ˑ53 | 657 (ˑ9) | 8ˑ92 | 0ˑ96 (0ˑ86, 1ˑ07) | 0ˑ45 |
Note: Overall long-term represents the entire period from randomization in ASPREE until Year 4 follow-up in ASPREE-XT (median of 88 years including a median of 47 years in the randomized treatment phase)
*
The first occurrence of any of the three components (death from any cause, dementia, or persistent physical disability) during the treatment phase and legacy follow-up.
†
For the secondary endpoints, all the participants who had an event at any time during the trial and legacy followup period are counted.